Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

Daniela Galimberti, Chiara Fenoglio, Carlo Lovati, Eliana Venturelli, Ilaria Guidi, Barbara Corrà, Diego Scalabrini, Francesca Clerici, Claudio Mariani, Nereo Bresolin, Elio Scarpini

Research output: Contribution to journalArticle

Abstract

Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules.

Original languageEnglish
Pages (from-to)1763-1768
Number of pages6
JournalNeurobiology of Aging
Volume27
Issue number12
DOIs
Publication statusPublished - Dec 2006

    Fingerprint

Keywords

  • Alzheimer's disease (AD)
  • Biomarker
  • Mild cognitive impairment (MCI)
  • Monocyte chemoattractant protein-1 (MCP-1)

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this